STOML1: Potential Drug Target Or Biomarker (G9399)

Target Name: STOML1

NCBI ID: G9399

STOML1

STOML1: Potential Drug Target Or Biomarker

STOML1 (SPEC-like protein 1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, lungs, and kidneys. It is a member of the spectin domain family of proteins, which are known for their ability to interact with other proteins and to play important roles in various cellular processes.

One of the unique features of STOML1 is its ability to form aggregates in the brain, which are thought to play a role in the development and progression of neurodegenerative diseases. aggregates of STOML1 have been observed in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

In addition to its role in neurodegenerative diseases, STOML1 has also been shown to be involved in various physiological processes in the body. For example, it has been shown to play a role in the regulation of ion and water balance in the kidneys, and it has been shown to interact with the protein known as TRPV4, which is involved in the sense of touch.

Another interesting property of STOML1 is its ability to interact with small molecules, such as drugs. This has led some researchers to consider the potential of STOML1 as a drug target or biomarker.

One way in which STOML1 might be targeted as a drug is through its role in the regulation of ion and water balance in the kidneys. Drugs that are designed to interfere with the function of STOML1, such as diuretics, have been shown to be effective in treating a variety of neurodegenerative diseases, including Alzheimer's disease.

Another potential way in which STOML1 might be used as a drug target is through its role in the regulation of pain. STOML1 has been shown to interact with the protein known as TRPV4, which is involved in the sense of pain. Drugs that are designed to interfere with the function of TRPV4, such as nonsteroidal anti-inflammatory drugs (NSAIDs), have been shown to be effective in treating a variety of pain conditions.

In addition to its potential as a drug target, STOML1 also has potential as a biomarker. The aggregates of STOML1 that have been observed in the brains of individuals with neurodegenerative disorders have been shown to be associated with the development and progression of these diseases. By detecting the presence of these aggregates using techniques such as immunofluorescence, researchers may be able to diagnose neurodegenerative diseases based on the level of STOML1 in the brain.

Overall, STOML1 is a protein that has the potential to be a drug target or biomarker. Its ability to form aggregates in the brain and its interaction with small molecules make it an attractive candidate for both drug development and diagnostic applications. Further research is needed to fully understand the role of STOML1 in various biological processes and to determine its potential as a drug or biomarker.

Protein Name: Stomatin Like 1

Functions: May play a role in cholesterol transfer to late endosomes (PubMed:19696025). May play a role in modulating membrane acid-sensing ion channels. Can specifically inhibit proton-gated current of ASIC1 isoform 1. Can increase inactivation speed of ASIC3. May be involved in regulation of proton sensing in dorsal root ganglions (By similarity). May play a role in protecting FBXW7 isoform 3 from degradation (PubMed:23082202)

The "STOML1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STOML1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets